Rifampicin in cutaneous leishmaniasis - A therapeutic trial in Saudi Arabia

Journal of Pakistan Association of Dermatologists

Volumn 16, Issue 1, 2006, Pages 4-9

  Jaffar, Huma ^a  

^a Bahrain Specialist Hospital   (Bahrain)

Author keywords

Cutaneous leishmaniasis; Rifampicin; Therapeutic trial

Indexed keywords

PLACEBO; RIFAMPICIN;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; HUMAN; LEISHMANIA; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; SKIN LEISHMANIASIS; TREATMENT RESPONSE; WOUND HEALING;

EID: 33747612877     PISSN: 15609014     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Onder M, Gurer MA. Leishmaniasis. In: Katsambas AD, Lotti TM, eds. European Handbook of Dermatological Treatment. London: Springer, 2000. p. 301-7.
2. Desjeux P. Cutaneous leishmaniasis: clinical aspects. In: Dowlati Y, Modabber F, eds. Clinics in Dermatology. New York: Elsevier. 1996. p. 417-23.
3. Peters W, Al-Zahrani MA. The leishmaniasis: a public health problem in Saudi Arabia. Saudi Med J 1987; 8: 333-43.
4. Rook A, Wilkinson DS, Ebling FTB et al. Textbook of Dermatology. Edinburgh: Blackwell Scientific Publication, 1986. p. 1021-65.
5. Gardener PJ, Shchory L. Chance ML. Species differentiation in the genus leishmania by morphometric studies with the electron microscope: Part 1. Ann Trop Med Parasitol 1977; 71: 147-56.
6. Sukkar F. Leishmaniasis in the Middle East. In: Chang KP, Brays RS, eds. Human Parasitic Disease, Vol. I. Amsterdam: Elsevier; 1985. p. 393-413.
7. Hepburn NC. Management of cutaneous leishmaniasis. Current Opinion Infectious Diseases 2001; 14: 151-4.
8. Alkhawaja AM, Iarbi E, Al-ghadin Y, Abahussein A, Jain S. Treatment of cutaneous leishmaniasis with antimony; intramuscular vs intralesional administration. Ann Trop Med Parasitol 1997; 91: 899-905.
9. Bryceson ADM. Leishmaniasis. In: Wyngaarden JB, Smith Jr LH, eds. Cecil's Textbook of Medicine. Edinburgh: Churchill Livingstone: 1980. p. 815-8.
10. Yardely V, Croft SL. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrobial agents and chemotherapy 1997; 41: 752.
11. Osorio LE. Treatment of cutaneous leishmaniasis in Columbia with dapsone. Lancet 1998; 351: 1176.
12. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin infect Dis 1997; 24: 684-703.
13. Kubba R, Al-Gindan Y, El-Hassan AM, Omer AHS. Ketoconazole in cutaneous leishmaniasis: results of a pilot study. Saudi Med J 1986; 7: 596-604.
14. Abdulwahab SA, Qasem AA, Nabeel NM, Amr IR. Cutaneous leishmaniasis in Kuwait, clinical experience with Itraconazole. Int J Dermatol 1991; 30: 237-9.
15. Hafez J, Al-Taqui M, Fowzy M et al. Cutaneous leishmaniasis in Kuwait: Part II. Therapeutic trial of Rifampicin and Pentostam. Arab J Med 1985; 4: 20-22.
16. Kochar DK, Aseri , Sharma BV, Bumb RA, Mehta RD, Purohit SK. The role of rifampicin in the management of cutaneous leishmaniasis. QJM 2000; 93: 733-738.
17. Chulay JD, Spencer HG, Mugambi M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Am J Trop Med Hyg 1985; 34: 702-9.
18. World Health Organization. Antimonials. Large scale failure in leishmaniasis "alarming." TDR News 1990:34.
19. Bahamdan K, Tallab TM, Nauri MM. Terbinafine in the treatment of cutaneous leishmaniasis: a pilot study. Int J Dermatol 1997; 36: 59.
20. Sharquie KE, Al-Talib KKA, Chu AC. Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. Br J Dermatol 1988; 119: 53-*
21. Aste N, Pau M, Biggio P. Intralesional treatment of cutaneous leishmaniasis with meglumine antimonite. Br J Dermatol 1998; 138: 370-*.
22. Soyuer U, Aktas E. Intralesional bleomycin therapy for leishmaniasis cutis. Arch Dermatol 1988; 124: 1571.
23. Bryceson ADM, Bell SA. Occlusive paromomycin for cutaneous leishmaniasis. Lancet 1997; 349: 1477-*.
24. El-On J, Jacobos GP, Weinrauch L. Topical chemotherapy of cutaneous leishmaniasis. Parasitol Today 1988; 4: 76-81.
25. Bassiouny A, Meshad M, Talaat M et al. Cryosurgery in cutaneous leishmaniasis. Br J Dermatol 1982; 107: 467-74.
26. Junaid AJN. Treatment of cutaneous leishmaniasis with infra-red heat. Int J Dermatol 1986; 25: 470-2.
27. Currie MA. Treatment of cutaneous leishmaniasis by curretage. Br Med J 1983; 287: 1105-6.
28. Long P. Cutaneous leishmaniasis treated with metronidazole. JAMA 1983; 223: 1378-9.
29. Pearson JK, Sawick S. Metronidazole therapy for cutaneous leishmaniasis. Arch Dermatol 1975; 111: 1343-4.
30. Kandil E. Treatment of cutaneous leishmaniasis with trimethoprimsulphamethoxazole. Dermatologica (Basel) 1973; 146: 303-30.
31. Selim MM, Kandil E. Rifampicin in the treatment of cutaneous leishmaniasis. J Kuwait Med Assoc 1972; 6: 159-63.
32. Pareek SS. Combination of sodium stibogluconate and rifampicin in cutaneous leishmaniasis. Int J Dermatol 1984; 23: 70-1.
33. Livshin R, El-On J, Weinrauch CL, Even-Paz Z. Therapeutic effect of rifampicin and isoniazid against L. major. Int J Dermatol 1983; 22: 61-3.
34. Khatri ML, Haider N. Cutaneous leishmaniasis in Yeman. Int J Dermatol 1999; 38: 587-90.